BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Kemas kini terakhir: semalam, 8:37AM

46.92

-0.09 (-0.19%)

Penutupan Terdahulu 47.01
Buka 47.21
Jumlah Dagangan 7,024,133
Purata Dagangan (3B) 15,512,116
Modal Pasaran 95,485,943,808
Harga / Pendapatan (P/E TTM) 17.51
Harga / Pendapatan (P/E Ke hadapan) 7.08
Harga / Jualan (P/S) 2.03
Harga / Buku (P/B) 5.57
Julat 52 Minggu
39.50 (-15%) — 63.33 (34%)
Tarikh Pendapatan 31 Jul 2025
Hasil Dividen (DY TTM) 3.88%
Margin Keuntungan 11.38%
Margin Operasi (TTM) 31.57%
EPS Cair (TTM) 2.68
Pertumbuhan Hasil Suku Tahunan (YOY) -5.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -95.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 293.85%
Nisbah Semasa (MRQ) 1.28
Aliran Tunai Operasi (OCF TTM) 14.31 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 13.93 B
Pulangan Atas Aset (ROA TTM) 7.24%
Pulangan Atas Ekuiti (ROE TTM) 31.99%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menurun Bercampur
Drug Manufacturers - General (Global) Menurun Bercampur
Stok Bristol-Myers Squibb Company Menurun Menaik

AISkor Stockmoo

0.8
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga 1.5
Purata Bergerak Teknikal 1.0
Osilator Teknikal -0.5
Purata 0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BMY 95 B 3.88% 17.51 5.57
JNJ 375 B 2.38% 17.35 4.81
ABBV 334 B 3.37% 80.54 237.28
PFE 144 B 5.00% 18.39 1.58
GSK 78 B 2.03% 18.27 3.97
LLY 701 B 0.53% 63.68 44.16

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.07%
% Dimiliki oleh Institusi 82.11%
81.0081.0072.0072.0063.0063.0054.0054.0045.0045.00Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
39.50 (-15%) — 63.33 (34%)
Julat Harga Sasaran
54.00 (15%) — 68.00 (44%)
Tinggi 68.00 (Jefferies, 44.93%) Beli
Median 55.00 (17.22%)
Rendah 54.00 (UBS, 15.09%) Pegang
Purata 59.40 (26.60%)
Jumlah 2 Beli, 3 Pegang
Harga Purata @ Panggilan 50.13
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Cantor Fitzgerald 23 Apr 2025 55.00 (17.22%) Pegang 48.53
22 Apr 2025 55.00 (17.22%) Pegang 49.82
Jefferies 23 Apr 2025 68.00 (44.93%) Beli 48.53
Piper Sandler 22 Apr 2025 65.00 (38.53%) Beli 49.82
UBS 11 Apr 2025 54.00 (15.09%) Pegang 50.71
Goldman Sachs 08 Apr 2025 55.00 (17.22%) Pegang 53.07

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
26 Jun 2025 Pengumuman U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
17 Jun 2025 Pengumuman Bristol Myers Squibb Announces Dividend
16 Jun 2025 Pengumuman Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
12 Jun 2025 Pengumuman Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025
12 Jun 2025 Pengumuman Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
11 Jun 2025 Pengumuman Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
10 Jun 2025 Pengumuman Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus roya...
02 Jun 2025 Pengumuman BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
28 May 2025 Pengumuman Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
28 May 2025 Pengumuman Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
22 May 2025 Pengumuman Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
21 May 2025 Pengumuman Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
16 May 2025 Pengumuman Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
12 May 2025 CNBC Trump's plan to slash drug prices may struggle to get off the ground – here's what to know 
06 May 2025 Pengumuman Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
24 Apr 2025 Pengumuman Bristol Myers Squibb Reports First Quarter Financial Results for 2025
24 Apr 2025 CNBC Bristol Myers Squibb tops quarterly estimates, hikes outlook as drugmaker braces for tariffs
22 Apr 2025 Pengumuman Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
17 Apr 2025 Pengumuman U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
15 Apr 2025 Pengumuman Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis
14 Apr 2025 Pengumuman Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
11 Apr 2025 Pengumuman U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma
11 Apr 2025 CNBC Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
09 Apr 2025 CNBC Pharmaceutical stocks rise as Trump pauses tariffs but not for China
08 Apr 2025 Pengumuman U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Deficient Unresectable or Metastatic Colorectal Cancer¹
Papar semua
Hasil Dividen (DY TTM) 3.88%
Purata Hasil Dividen 5T 3.55%
Nisbah Pembayaran 91.04%
Jangkaan Pembayaran Dividen Seterusnya Nov 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Tunai
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Tunai
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Tunai
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Tunai
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Tunai
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Tunai
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Tunai
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Tunai
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Tunai
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Tunai
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Tunai
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Tunai
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Tunai
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Tunai
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Tunai
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Tunai
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Tunai
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Tunai
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Tunai
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Tunai
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Tunai
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Tunai
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Tunai
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Tunai
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Tunai
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Tunai
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Tunai
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Tunai
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Tunai
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Tunai
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Tunai
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Tunai
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Tunai
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Tunai
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Tunai
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Tunai
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Tunai
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Tunai
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Tunai
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Tunai
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Tunai
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Tunai
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Tunai
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Tunai
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Tunai
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Tunai
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.620 1 1.32
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Papar semua
48.4748.4747.6347.6346.8046.8045.9645.9645.1345.13Jun 24Jun 24Jun 25Jun 25Jun 26Jun 26Jun 27Jun 27Jun 30Jun 30Jul 1Jul 1Jul 2Jul 2Jul 3Jul 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.2000.200-0.000-0.000-0.200-0.200-0.400-0.400-0.600-0.600MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda